Aptar Q2 sales rise 6% to $966 mln, beat estimates
Overview
Aptar Q2 sales rise 6% yr/yr to $966 mln, beating analyst expectations
Adjusted EPS for Q2 beats consensus, rising 18% to $1.66
Co returns $100 mln to shareholders via dividends and share repurchases
Outlook
Aptar expects Q3 EPS between $1.53 and $1.61
Aptar sees challenges from normalizing naloxone sales
Company expects modest Q3 contributions from Closures and Beauty
Result Drivers
PHARMA SEGMENT - Strong demand in Prescription, Injectables, and Active Material Science divisions drove sales growth
BEAUTY SEGMENT - Growth in personal care products offset by lower demand in beauty dispensing technologies due to tariff uncertainties
CLOSURES SEGMENT - Increased demand in food and beverage markets across regions and applications fueled sales growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales | Beat | $966 mln | $956 mln (5 Analysts) |
Q2 Adjusted EPS | Beat | $1.66 | $1.56 (6 Analysts) |
Q2 EPS |
| $1.67 |
|
Q2 Net Income |
| $112 mln |
|
Q2 Adjusted EBITDA | Beat | $218 mln | $210.50 mln (5 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the non-paper containers & packaging peer group is "buy"
Wall Street's median 12-month price target for Aptargroup Inc is $175.00, about 10.2% above its July 31 closing price of $157.14
The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 26 three months ago
Press Release: ID:nBw8Xy1s8a
